Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 4
2017 4
2018 3
2019 4
2020 7
2021 2
2022 2
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients.
Goutakoli P, Papadaki G, Repa A, Avgoustidis N, Kalogiannaki E, Flouri I, Bertsias A, Zoidakis J, Samiotaki M, Bertsias G, Semitekolou M, Verginis P, Sidiropoulos P. Goutakoli P, et al. Among authors: bertsias a. Cells. 2023 Dec 9;12(24):2808. doi: 10.3390/cells12242808. Cells. 2023. PMID: 38132128 Free PMC article.
Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study.
Flouri I, Goutakoli P, Repa A, Bertsias A, Avgoustidis N, Eskitzis A, Pitsigavdaki S, Kalogiannaki E, Terizaki M, Bertsias G, Sidiropoulos P. Flouri I, et al. Among authors: bertsias a. Rheumatol Int. 2024 Feb;44(2):249-261. doi: 10.1007/s00296-023-05455-7. Epub 2023 Oct 10. Rheumatol Int. 2024. PMID: 37815625 Free PMC article.
Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
Nikoloudaki M, Nikolopoulos D, Koutsoviti S, Flouri I, Kapsala N, Repa A, Katsimbri P, Theotikos E, Pitsigavdaki S, Pateromichelaki K, Bertsias A, Elezoglou A, Sidiropoulos P, Fanouriakis A, Boumpas D, Bertsias G. Nikoloudaki M, et al. Among authors: bertsias a. Front Immunol. 2023 Jan 4;13:1074044. doi: 10.3389/fimmu.2022.1074044. eCollection 2022. Front Immunol. 2023. PMID: 36685524 Free PMC article.
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study.
Bertsias A, Avgoustidis N, Papalopoulos I, Repa A, Kougkas N, Kalogiannaki E, Bertsias G, Flouri I, Sidiropoulos P. Bertsias A, et al. Arthritis Res Ther. 2022 Jun 2;24(1):132. doi: 10.1186/s13075-022-02826-6. Arthritis Res Ther. 2022. PMID: 35655317 Free PMC article.
Cognitive Impairment and Dementia in Primary Care: Current Knowledge and Future Directions Based on Findings From a Large Cross-Sectional Study in Crete, Greece.
Bertsias A, Symvoulakis E, Tziraki C, Panagiotakis S, Mathioudakis L, Zaganas I, Basta M, Boumpas D, Simos P, Vgontzas A, Lionis C. Bertsias A, et al. Front Med (Lausanne). 2020 Nov 23;7:592924. doi: 10.3389/fmed.2020.592924. eCollection 2020. Front Med (Lausanne). 2020. PMID: 33330553 Free PMC article.
32 results